Abstract
Ophthalmology faces many challenges in providing effective and meaningful eye care to an ever-increasing group of people. Even health systems that have so far been able to cope with the quantitative patient increase, due to their funding and the availability of highly qualified professionals, and improvements in practice routine efficiency, will be pushed to their limits. Further pressure on care will also be caused by new active substances for the largest group of patients with AMD, the so-called dry form. Treatment availability for this so far untreated group will increase the volume of patients 2–3 times. Without the adaptation of the care structures, this quantitative and qualitative expansion in therapy will inevitably lead to an undersupply.There is increasing scientific evidence that significant efficiency gains in the care of chronic diseases can be achieved through better networking of stakeholders in the healthcare system and greater patient involvement. Digitalization can make an important contribution here. Many technological solutions have been developed in recent years and the time is now ready to exploit this potential. The exceptional setting during the SARS-CoV-2 pandemic has shown many that new technology is available safely, quickly, and effectively. The emergency has catalyzed innovation processes and shown for post-pandemic time after that we are equipped to tackle the challenges in ophthalmic healthcare - ultimately for the benefit of patients and society.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Data availability
No research data are provided in this manuscript.
References
Faes L, Rosenblatt A, Schwartz R, Touhami S, Ventura CV, Chatziralli IP, et al. Overcoming barriers of retinal care delivery during a pandemic-attitudes and drivers for the implementation of digital health: a global expert survey. Br J Ophthalmol. 2021;105:1738–43.
Herzlinger RE. Why innovation in health care is so hard. Harv Bus Rev. 2006. https://hbr.org/2006/05/why-innovation-in-health-care-is-so-hard
Hjelm NM. Benefits and drawbacks of telemedicine. J Telemed Telecare. 2005;11:60–70.
Wasan KM, Berry L, Kalra J. Physician centric healthcare: is it time for a paradigm shift? J R Soc Med. 2017;110:295–6.
Noah B, Keller MS, Mosadeghi S, Stein L, Johl S, Delshad S, et al. Impact of remote patient monitoring on clinical outcomes: an updated meta-analysis of randomized controlled trials. NPJ Digit Med. 2018;1:20172.
Polinski JM, Kowal MK, Gagnon M, Brennan TA, Shrank WH. Home infusion: Safe, clinically effective, patient preferred, and cost saving. Health. 2017;5:68–80.
Abramoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med. 2018;1:39.
Chopra R, Wagner SK, Keane PA. Optical coherence tomography in the 2020s-outside the eye clinic. Eye. 2021;35:236–43.
Choremis J, Chow DR. Use of telemedicine in screening for diabetic retinopathy. Can J Ophthalmol. 2003;38:575–9.
Faes L, Fu DJ, Huemer J, Kern C, Wagner SK, Fasolo S, et al. A virtual-clinic pathway for patients referred from a national diabetes eye screening programme reduces service demands whilst maintaining quality of care. Eye. 2021;35:2260–9.
Faes L, Islam M, Bachmann LM, Lienhard KR, Schmid MK, Sim DA. False alarms and the positive predictive value of smartphone-based hyperacuity home monitoring for the progression of macular disease: a prospective cohort study. Eye. 2021;35:3035–40.
Gross N, Bachmann LM, Islam M, Faes L, Schmid MK, Thiel MA, et al. Visual outcomes and treatment adherence of patients with macular pathology using a mobile hyperacuity home-monitoring app: a matched-pair analysis. BMJ Open. 2021;11:e056940.
Group AHSR, Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 2014;121:535–44.
Gupta A, Cavallerano J, Sun JK, Silva PS. Evidence for Telemedicine for Diabetic Retinal Disease. Semin Ophthalmol. 2017;32:22–8.
Islam M, Sansome S, Das R, Lukic M, Chong Teo KY, Tan G, et al. Smartphone-based remote monitoring of vision in macular disease enables early detection of worsening pathology and need for intravitreal therapy. BMJ Health Care Inform. 2021;28:1–7.
Keenan TDL, Goldstein M, Goldenberg D, Zur D, Shulman S, Loewenstein A. Prospective, longitudinal pilot study: daily self-imaging with patient-operated home OCT in neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1. https://doi.org/10.1016/j.xops.2021.100034.
Korot E, Pontikos N, Drawnel FM, Jaber A, Fu DJ, Zhang G, et al. Enablers and barriers to deployment of smartphone-based home vision monitoring in clinical practice settings. JAMA Ophthalmol. 2022;140:153–60.
Maloca P, Hasler PW, Barthelmes D, Arnold P, Matthias M, Scholl HPN, et al. Safety and feasibility of a novel sparse optical coherence tomography device for patient-delivered retina home monitoring. Transl Vis Sci Technol. 2018;7:8.
Scanlon PH. The English National Screening Programme for diabetic retinopathy 2003-2016. Acta Diabetol. 2017;54:515–25.
Schmid MK, Thiel MA, Lienhard K, Schlingemann RO, Faes L, Bachmann LM. Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration. Eye. 2019;33:1584–9.
Shi L, Wu H, Dong J, Jiang K, Lu X, Shi J. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol. 2015;99:823–31.
Vukicevic M, Heraghty J, Cummins R, Gopinath B, Mitchell P. Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration. Eye. 2016;30:413–21.
Westborg I, Rosso A. Risk factors for discontinuation of treatment for neovascular age-related macular degeneration. Ophthalmic Epidemiol. 2018;25:176–82.
Teo KYC, Bachmann LM, Sim D, Lee SY, Tan A, Wong TY, et al. Patterns and characteristics of a clinical implementation of a self-monitoring program for retina diseases during the COVID-19 pandemic. Ophthalmol Retin. 2021;5:1245–53.
Patel S, Hamdan S, Donahue S. Optimising telemedicine in ophthalmology during the COVID-19 pandemic. J Telemed Telecare. 2022;28:498–501.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106–16.
Chopra R, Preston GC, Keenan TDL, Mulholland P, Patel PJ, Balaskas K, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye. 2022;36:1373–8.
Apellis Pharmaceuticals I. Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration. 2021. https://www.clinicaltrialsgov/ct2/show/NCT03525600.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.
Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129:295–307.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741–55.
Kuhn TS. The Structure of Scientific Revolutions. Chicago: University of Chicago Press; 1970.
Ho AC, Heier JS, Holekamp NM, Garfinkel RA, Ladd B, Awh CC, et al. Real-world performance of a self-operated home monitoring system for early detection of neovascular age-related macular degeneration. J Clin Med. 2021;10:1355.
Geschwindner H. 2021. https://www.gerontologieblog.ch/augenmobil-bringt-die-augenheilkunde-ins-pflegezentrum/.
Jones L, Bryan SR, Miranda MA, Crabb DP, Kotecha A. Example of monitoring measurements in a virtual eye clinic using ‘big data’. Br J Ophthalmol. 2018;102:911–5.
Kern C, Fu DJ, Kortuem K, Huemer J, Barker D, Davis A, et al. Implementation of a cloud-based referral platform in ophthalmology: making telemedicine services a reality in eye care. Br J Ophthalmol. 2020;104:312–7.
Saleem SM, Pasquale LR, Sidoti PA, Tsai JC. Virtual ophthalmology: telemedicine in a COVID-19 era. Am J Ophthalmol. 2020;216:237–42.
Author information
Authors and Affiliations
Contributions
LF, DAS, and LMB initiated the project and wrote a first draft of the text. All authors made textual additions and provided critical intellectual input. All authors approved the content of the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Faes, L., Maloca, P.M., Hatz, K. et al. Transforming ophthalmology in the digital century—new care models with added value for patients. Eye 37, 2172–2175 (2023). https://doi.org/10.1038/s41433-022-02313-x
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-022-02313-x
